Evergreen Deception: How Big Pharma's Patent Gaming Keeps Generic Drugs Off Shelves and Patients in Crisis
Drug manufacturers have spent decades perfecting a legal strategy that extends monopoly pricing on life-saving medications long after original patents expire — a practice known as evergreening that costs American patients and taxpayers hundreds of billions of dollars annually. While patients ration insulin and cancer drugs, pharmaceutical companies post record profits and bipartisan reform legislation quietly dies in the Senate.